Early experience of fontolizumab, a humanised anti‐interferon γ antibody, in active Crohn's disease has shown that the drug caused a significant decrease in endoscopic severity scores and CRP and was reasonably well tolerated. Fontolizumab may be worthy of further clinical trials
No takes yet. Share an insight, caveat, or question.
Subrata Ghosh (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: